Researchers at Washington University injected an antibody that blocks CXCR3 in a mouse model of tauopathy. Treated animals showed about half as many T cells in the brain, retained roughly 40% more tissue in memory centers, and performed better on a memory test despite unchanged tau levels.
Blocking the chemokine receptor CXCR3 on T cells cut brain T cell infiltration roughly in half and reduced neurodegeneration in a mouse tauopathy model.
Treated mice retained about 40% more tissue in brain memory regions and had better memory performance, even though soluble and insoluble tau levels were unchanged.
CXCL10 chemokine in the brain and CXCR3 on activated T cells form a chemotactic axis that links peripheral immune activation to tau-driven brain injury.
# What the study tested Researchers at Washington University School of Medicine tested whether blocking T cell entry into the brain could reduce neurodegeneration in tauopathies. They focused on the chemokine axis formed by CXCL10 (a chemokine elevated in the tau mouse model and in Alzheimer's) and its receptor CXCR3, which is present on activated T cells.
# Main result in plain terms Injecting an anti-CXCR3 antibody into young mice with brain tau accumulation (before major cell loss) every five days for about three and a half months reduced T cell numbers in the brain by about half. Treated mice retained roughly 40% more tissue in memory centers and performed better on a memory test than untreated mice. Levels of soluble and insoluble tau were not changed by the treatment.
# Why this matters
# Mechanism tested and evidence
These results support a chemotactic pathway: elevated CXCL10 in the brain creates a gradient that CXCR3-expressing activated T cells follow to enter the brain and contribute to neuron loss.
# Experimental endpoints reported
# Implications for therapy development The findings point to peripheral immune-cell trafficking as a targetable contributor to neuron loss in tauopathies. Blocking the CXCR3 axis prevented T cell brain entry and produced neuroprotection in the mouse model, suggesting a potential complementary or alternative therapeutic route to direct anti-tau or anti-amyloid strategies. The authors describe CXCR3 as a critical target for mitigating CD4+ and CD8+ T cell infiltration and conferring neuroprotection in vivo.
# What remains open
Scientists found that immune cells contributing to Alzheimer’s-related brain damage may be activated in lymph nodes outside the brain before traveling into the nervous system. Blocking this pathway in mice dramatically reduced neurodegeneration and preserved cognitive abilities, pointing to a potentially more accessibl
A study in mice traces immune cells that drive neurodegeneration to the body’s lymph nodes, suggesting that processes outside the brain contribute to the damage seen in various tauopathies. The post Immune Cells Driving Alzheimer’s-Like Neurodegeneration Traced to Lymph Nodes appeared first on GEN - Genetic Engineering
A study found that immune cells that drive neurodegeneration, the progressive damage and loss of nerve cells, originate in the body’s lymph nodes. In mice whose brains accumulate clumps of tau protein, researchers found a way to protect nerve cells without clearing away those clumps. They interrupted an immune response
Many of the more sophisticated forms of medicine, including gene therapies and immunotherapies, are challenging to deliver to the brain. At the very least there are far fewer practical options for delivery, and it is possible that none of that that exist fit a given desired use case. The blood-brain barrier stands in t
The strongest binder from a primary screen is not necessarily the best drug starting point. Peptide discovery campaigns should capture molecular architecture, biological context, time, and developability from the outset. The post Designing Peptide Screens to Generate Knowledge, Not Just Hits appeared first on GEN - Gen
Sponsored content brought to you by Artificial intelligence is dramatically accelerating early drug discovery. Models can screen chemical space, predict structures, optimize properties, and propose new molecules at speeds that were unimaginable […] The post AI Drug Discovery Hits a New Bottleneck: Experimental Validati
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.